Pancreatic Cancer Research

Clinical trialPhase 2Completed

Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer

Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma

NCT02749136↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Finished, no results posted
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
May 2016
Expected end
November 2019
Enrollment
44 participants
Sites
1
Primary outcomes
1-year progression-free survival (PFS) rate
Sponsor
Other
Results posted
No
Last update
25 November 2019

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 10